GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » AS Latvijas Juras medicinas centrs (ORSE:LJM1R) » Definitions » Return-on-Tangible-Equity

AS Latvijas Juras medicinas centrs (ORSE:LJM1R) Return-on-Tangible-Equity : 5.60% (As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is AS Latvijas Juras medicinas centrs Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. AS Latvijas Juras medicinas centrs's annualized net income for the quarter that ended in Mar. 2024 was €0.36 Mil. AS Latvijas Juras medicinas centrs's average shareholder tangible equity for the quarter that ended in Mar. 2024 was €6.50 Mil. Therefore, AS Latvijas Juras medicinas centrs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 5.60%.

The historical rank and industry rank for AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity or its related term are showing as below:

ORSE:LJM1R' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -5.85   Med: 3.99   Max: 23.48
Current: 3.18

During the past 13 years, AS Latvijas Juras medicinas centrs's highest Return-on-Tangible-Equity was 23.48%. The lowest was -5.85%. And the median was 3.99%.

ORSE:LJM1R's Return-on-Tangible-Equity is ranked worse than
66.17% of 541 companies
in the Healthcare Providers & Services industry
Industry Median: 10.62 vs ORSE:LJM1R: 3.18

AS Latvijas Juras medicinas centrs Return-on-Tangible-Equity Historical Data

The historical data trend for AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AS Latvijas Juras medicinas centrs Return-on-Tangible-Equity Chart

AS Latvijas Juras medicinas centrs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.97 14.84 9.52 -0.21

AS Latvijas Juras medicinas centrs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.01 -3.92 16.83 -5.82 5.60

Competitive Comparison of AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity

For the Medical Care Facilities subindustry, AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity falls into.



AS Latvijas Juras medicinas centrs Return-on-Tangible-Equity Calculation

AS Latvijas Juras medicinas centrs's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-0.014/( (6.806+6.712 )/ 2 )
=-0.014/6.759
=-0.21 %

AS Latvijas Juras medicinas centrs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=0.364/( (6.712+6.295)/ 2 )
=0.364/6.5035
=5.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


AS Latvijas Juras medicinas centrs  (ORSE:LJM1R) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


AS Latvijas Juras medicinas centrs Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of AS Latvijas Juras medicinas centrs's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


AS Latvijas Juras medicinas centrs (ORSE:LJM1R) Business Description

Traded in Other Exchanges
N/A
Address
Patversmes iela 23, Riga, LVA, LV-1005
AS Latvijas Juras medicinas centrs is engaged in the provision of healthcare services. It operates hospitals and diagnostic centers. The company offers diagnostics services, magnetic resonance imaging, radiological diagnostics services, and ambulance services. It is also engaged in General medical practice activities, Special medical practice activities, Residential nursing care activities, Retail sale of medical and orthopedic goods in specialized stores, and Other personal service activities. The majority of the revenue is generated from the Ambulatory Medical Services.

AS Latvijas Juras medicinas centrs (ORSE:LJM1R) Headlines

No Headlines